« Previous
Next »
Titles
- CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments1
- Calculation of potential inflation-indexed rebates for Medicare Part B drugs1
- Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs1
- Competitive bidding in drug procurement: evidence from China1
